Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Galapagos Presents Superior Potentiator Series for CF

Published: Friday, October 18, 2013
Last Updated: Friday, October 18, 2013
Bookmark and Share
Novel proprietary series to start clinical trials end of 2014.

Galapagos NV has developed a series of novel potentiators in its cystic fibrosis program. The data will be presented at the North American Cystic Fibrosis Conference taking place from 17 - 19 October in Salt Lake City, Utah.

In its CF research program, Galapagos developed novel potentiator series that are highly potent and that show superior opening of the defective CFTR channel in comparison to Kalydeco®.

This was shown in assays of cells that carry a CFTR class II, III or IV mutation. Furthermore, the superior channel opening was confirmed in primary cells from F508del and G551D patients.

In addition to its efficacy, the Galapagos series show good metabolic stability and permeability and favorable PK profiles. In comparison to Kalydeco®, the new potentiators have a superior in vitro safety profile, including a clean CYP profile and high selectivity.

These results encourage Galapagos to nominate a pre-clinical candidate from this series at the end of this year, with the first clinical trials starting at the end of 2014. Galapagos has pending patents on these novel potentiators.

Galapagos initiated its research in CF in 2005 as part of a collaboration with the Cystic Fibrosis Foundation. In 2010 Galapagos decided to pursue CF as the first orphan disease in which the company is attempting to discover, develop and launch its own medicines.

In September 2013 Galapagos signed an agreement with AbbVie where they will work collaboratively to develop and commercialize oral drugs that address the main mutations in CF patients, including F508del and G551D.

Galapagos will present its novel potentiators at a poster session (abstract #41) at NACFC on 17 October at 11:50 am and 18 October at 4 pm.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

DARWIN 2 24-week Monotherapy Data in RA Confirm Previous Results
Safety profile in DARWIN 2 consistent with previous filgotinib RA studies.
Tuesday, August 25, 2015
Patient Recruitment Completed in FITZROY Phase 2 Crohn's Disease Study
First selective JAK1 inhibitor in Phase 2 in Crohn's disease.
Friday, August 07, 2015
Galapagos Completes Recruitment for ORIGIN Phase 2 Trial
Recruitment for the Phase 2 Proof-of-Concept study with GPR84 inhibitor GLPG1205 in ulcerative colitis patients.
Saturday, June 20, 2015
Galapagos DARWIN 1 and 2 Studies have Completed 24 Weeks of Treatment
Topline results from final analyses expected to be released in July and August 2015.
Thursday, June 11, 2015
Galapagos Regains Rights to GLPG1690
Filing for Phase 2 clinical trial in 2015.
Thursday, March 19, 2015
Galapagos Receives €1.6 Million IWT Grant for Hepatitis B Program
Research will focus on compounds against viral protein targets and on inhibitors of host cell proteins.
Thursday, February 12, 2015
Galapagos Receives €2.5 Million IWT Grant for Antibiotic Research
Grant to support the development of Galapagos’ novel antibiotics in a collaboration project.
Saturday, January 24, 2015
Galapagos Completes Recruitment for Darwin 2 Monotherapy Study
Study will begin a series of topline readouts starting around end of the first quarter 2015.
Monday, November 24, 2014
Galapagos Presents Favorable Phase 1 Data for IBD Target
Galapagos NV discloses GPR84 as a promising novel target for treating inflammatory bowel disease during an oral presentation at United European Gastroenterology Week in Vienna.
Tuesday, October 21, 2014
Bart Filius Joins Galapagos as CFO
Bart will join the Executive Committee of Galapagos and be responsible for Finance, Investor Relations, IT, and Purchasing.
Saturday, October 18, 2014
Galapagos Receives Milestone in Osteoarthritis Alliance with Servier
Company completes the nomination of new pre-clinical candidate in the alliance with Servier.
Thursday, August 07, 2014
Galapagos Receives €2 Million from Osteoarthritis Alliance with Servier
Company is responsible for discovery and development of new candidate drugs.
Tuesday, March 11, 2014
Galapagos Receives €2.3 Million IWT Grant for Fibrosis Research
Aim of IWT grant is to deliver a comprehensive fibrosis research platform.
Tuesday, February 04, 2014
Galapagos Receives €2.9 Million IWT Grant for Cystic Fibrosis Research
Project to identify and progress multiple promising CF therapies towards pre-clinical candidates.
Monday, January 13, 2014
Galapagos Selects Pre-Clinical Candidate for Cystic Fibrosis
Start of Phase 1 expected before end 2014.
Tuesday, December 17, 2013
Scientific News
The Changing Tides of the In Vitro Diagnostics Market
With the increasing focus in personalized medicine, diagnostics plays a crucial role in patient monitoring.
Immunotherapy Agent Benefits Patients with Drug-Resistant Multiple Myeloma in First Human Trial
Daratumumab proved generally safe in patients, even at the highest doses.
Low-level Arsenic Exposure Before Birth Associated with Early Puberty in Female Mice
Study examine whether low-dose arsenic exposure could have similar health outcomes in humans.
Inciting an Immune Attack On Cancer Cells
A new minimally invasive vaccine that combines cancer cells and immune-enhancing factors could be used clinically to launch a destructive attack on tumors.
‘Mutation-Tracking’ Blood Test for Breast Cancer
Scientists have developed a blood test for breast cancer able to identify which patients will suffer a relapse after treatment, months before tumours are visible on hospital scans.
Cellular Contamination Pathway for Heavy Elements Identified
Berkeley Lab scientists find that an iron-binding protein can transport actinides into cells.
Intensity of Desert Storms May Affect Ocean Phytoplankton
MIT study finds phytoplankton are extremely sensitive to changing levels of desert dust.
Common ‘Heart Attack’ Blood Test May Predict Future Hypertension
Small rises in troponin levels may have value as markers for subclinical heart damage and high blood pressure.
LaVision BioTec Reports on the Neuro Research on the Human Brain After Trauma
Company reports on the work of Dr Ali Ertürk from the Institute for Stroke and Dementia Research at LMU Munich.
NIH Study Shows No Benefit of Omega-3 Supplements for Cognitive Decline
Research was published in the Journal of the American Medical Association.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!